Lyora Therapeutics is developing a portfolio of genetic medicines aimed at inherited retinal diseases that currently lack available treatments. Its lead program, LYA-101, targets retinitis pigmentosa caused by pathogenic variants in PRPF31 and is designed to augment PRPF31 expression. A second program, LYA-102, targets Usher Syndrome Type 2 using an optimized CRISPR approach to address mutations in exon 13 of USH2A. The company reports that its pipeline programs are biologically validated with preclinical proof-of-concept data suggesting potential one-and-done therapies that could stop disease progression and, in some cases, improve vision. Lyora raised $2.5M in a pre-seed round to advance these programs, and has appointed Pam Stetkiewicz, PhD, as CEO.

Total raised

$3M

Funding rounds

1

Latest round

Seed

Latest activity

Jul 2026